Pfizer, Samsung Biologics build on biosimilar deals now worth $897M
Pfizer has expanded upon a pair of agreements with Samsung Biologics to make its biosimilars in a deal worth almost $900 million.
According to a fact sheet sent to Endpoints News, Samsung Biologics and Pfizer said they increased one agreement, signed in March, to $193 million, and amended a second agreement, announced in June, to $704 million.
The companies did not disclose what products Samsung will be manufacturing, though the South Korean manufacturer said the deal calls for multiple products to be produced, which is different from more conventional contracts that are usually for one product.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
